Clearmind Medicine (NASDAQ: CMND) furnishes 6-K on MEAI AUD review

Rhea-AI Filing Summary

Clearmind Medicine Inc. filed a Form 6-K as a foreign private issuer, furnishing a press release dated December 12, 2025. The press release is titled “Clearmind Medicine’s MEAI Spotlighted in Prestigious Review: Leading Experts Affirm Transformative Potential for Alcohol Use Disorder Treatment.” This filing formally provides that communication to investors and regulators under the Securities Exchange Act of 1934.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of: December 2025

Commission file number: 001-41557

CLEARMIND MEDICINE INC.

(Translation of registrant’s name into English)

101 – 1220 West 6th Avenue

Vancouver, British Columbia

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒       Form 40-F ☐

CONTENTS

Attached hereto and incorporated herein is the Registrant’s press release issued on December 12, 2025, titled “Clearmind Medicine’s MEAI Spotlighted in Prestigious Review: Leading Experts Affirm Transformative Potential for Alcohol Use Disorder Treatment”.

1

EXHIBIT INDEX

Exhibit No.
99.1		Press release titled: “Clearmind Medicine’s MEAI Spotlighted in Prestigious Review: Leading Experts Affirm Transformative Potential for Alcohol Use Disorder Treatment”

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Clearmind Medicine, Inc.
	(Registrant)
Date: December 12, 2025	By:	/s/ Adi Zuloff-Shani
	Name:	Adi Zuloff-Shani
	Title:	Chief Executive Officer

3

FAQ

What did Clearmind Medicine Inc. (CMND) file with the SEC?

Clearmind Medicine Inc. filed a Form 6-K, which is a report of a foreign private issuer used to furnish information to the SEC and investors.

What is the main subject of Clearmind Medicine’s December 2025 Form 6-K?

The filing furnishes a press release titled “Clearmind Medicine’s MEAI Spotlighted in Prestigious Review: Leading Experts Affirm Transformative Potential for Alcohol Use Disorder Treatment.”

When was the Clearmind Medicine press release referenced in the Form 6-K issued?

The press release attached to the filing was issued on December 12, 2025.

What document is attached as Exhibit 99.1 in Clearmind Medicine’s Form 6-K?

Exhibit 99.1 is the press release titled “Clearmind Medicine’s MEAI Spotlighted in Prestigious Review: Leading Experts Affirm Transformative Potential for Alcohol Use Disorder Treatment.”

Who signed the Clearmind Medicine (CMND) Form 6-K?

The Form 6-K was signed on behalf of Clearmind Medicine Inc. by Adi Zuloff-Shani, the company’s Chief Executive Officer, dated December 12, 2025.

Where is Clearmind Medicine Inc. headquartered according to the Form 6-K?

The company lists its principal executive offices at 101 – 1220 West 6th Avenue, Vancouver, British Columbia.